Abstract
New Zealand (NZ) became one of few countries to shift from PCV13 to PCV10 in 2017. The number of serotype 19A cases in young children and the proportion of isolates that are penicillin-resistant have been steadily increasing since. It is time for NZ to reconsider its choice of pneumococcal vaccine.